BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33268268)

  • 21. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
    Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
    Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
    Cecchini M; Miccio JA; Pahade J; Lacy J; Salem RR; Johnson SB; Blakaj A; Stein S; Kortmansky JS; Johung KL
    Pancreas; 2020 Aug; 49(7):904-911. PubMed ID: 32658074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.
    Temraz S; Nassar F; Hammoud MS; Mukherji D; O'Reilly EM; Dbouk H; Farhat F; Charafeddine M; Faraj W; Khalifeh MJ; Abou-Alfa GK; Shamseddine A
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):735-742. PubMed ID: 35362216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
    Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
    Front Oncol; 2020; 10():1112. PubMed ID: 32850319
    [No Abstract]   [Full Text] [Related]  

  • 26. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry.
    Sternby H; Andersson B
    Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer.
    Williams JL; Kadera BE; Nguyen AH; Muthusamy VR; Wainberg ZA; Hines OJ; Reber HA; Donahue TR
    J Gastrointest Surg; 2016 Jul; 20(7):1331-42. PubMed ID: 27114246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
    Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
    Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
    Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
    Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraoperative paraaortic lymph node sampling during resection for pancreatic cancer: evolving role in the modern chemotherapy era.
    Kazami Y; Oba A; Ono Y; Sato T; Inoue Y; Saiura A; Takahashi Y; Ito H
    HPB (Oxford); 2023 Oct; 25(10):1169-1178. PubMed ID: 37357111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
    Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
    J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
    da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
    Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma.
    Brown ZJ; Shannon AH; Cloyd JM
    Minerva Surg; 2024 Jun; 79(3):315-325. PubMed ID: 38385797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery.
    Ariake K; Mizuma M; Motoi F; Maeda S; Morikawa T; Ishida M; Ohtsuka H; Aoki S; Miura T; Takadate T; Nakagawa K; Kamei T; Unno M
    Ann Surg Oncol; 2021 Oct; 28(11):6246-6254. PubMed ID: 33611747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis.
    Mataki Y; Kurahara H; Idichi T; Tanoue K; Hozaka Y; Kawasaki Y; Iino S; Maemura K; Shinchi H; Ohtsuka T
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
    Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
    Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Borderline resectable pancreatic cancer.
    Hackert T; Ulrich A; Büchler MW
    Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.